In recent years there has been an increase in multi-drug resistance (MDR) amongst gram-positive pathogens. This has impacted both hospital and community acquired infections.
The MICRONAUT-S plates are designed to provide the routine laboratory with an efficient tool for phenotypic detection of the important resistance mechanisms among these bacteria. The MICRONAUT-S MRSA/GP also includes highly effective backup antibiotics: ceftaroline, daptomycin, linezolid, tigecycline, vancomycin, and teicoplanin.
The susceptibility testing is based on the rehydration of antibiotics by adding a standardized bacteria suspension (Mueller Hinton Broth, cation adjusted (CAMHB)). The result is measured photometrically after 18-24 hours incubation at 35-37°C. Results are measured and interpreted either with the MICRONAUT software or visually.
Due to a special vacuum drying method, the plates can be stored at a room temperature of 15-25°C. The MICRONAUT test plates have a shelf life of 24 months at date of production.
The antibiotics configuration of the MICRONAUT-S MRSA/GP plate allows the specific detection of the clinically relevant single or multi-resistances of gram-positive bacteria in nosocomial infections.
The susceptibility testing with highly effective reserve antibiotics like ceftaroline offers the user alternatives in case of extreme multi-resistance. The MICRONAUT-S MRSA/GP offers the following features and benefits.
Please contact your local representative for availability in your country.
Not for sale in the USA.
As of January 2022, the Legal Manufacturer of all MICRONAUT products is Bruker Daltonics GmbH & Co. KG.